Recent advances in the characterisation of the platelet membrane system by proteomics

Current Pharmaceutical Design

Volumn 13, Issue 26, 2007, Pages 2647-2655

  Foy, Martina ^a   Maguire, Patricia B ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Lipid raft; Mass spectrometry; Membrane; Platelet; Proteomics; Receptors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALPHA ACTININ; ALPHA2 INTEGRIN; ALPHA2B INTEGRIN; ANTICOAGULANT AGENT; ANTIGEN; BETA3 INTEGRIN; CD109 ANTIGEN; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FILAMIN A; FLOTILLIN 1; GLYCOPROTEIN IB ALPHA; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; PROTEIN KINASE LYN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RAB PROTEIN; RAP PROTEIN; RAS PROTEIN; STOMATIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 23; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VINCULIN;

BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHROMATOGRAPHY; CLINICAL TRIAL; COMBINED FRACTIONAL DIAGONAL CHROMATOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; HOMEOSTASIS; HUMAN; LIPID RAFT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ISOLATION; PROTEOMICS; REVIEW; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE MEMBRANE; THROMBOSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMALS; BLOOD PLATELETS; CELL MEMBRANE; HUMANS; PLATELET MEMBRANE GLYCOPROTEINS; PROTEOMICS;

EID: 34548763149     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781662911     Document Type: Review

References (87)

1. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J 1993; 7(2): 308-166.
2. Clemetson KJ. Platelet activation: Signal transduction via membrane receptors. Thromb Haemost 1995; 74(1): 111-6.
3. Smyth SS, Parise LV. Regulation of ligand binding to glycoprotein IIb-IIIa (integrin alpha IIb beta 3) in isolated platelet membranes. Biochem J 1993; 292 (Pt 3): 749-58.
4. Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: The responsive integrin. Cell 1991; 65(3): 359-62.
5. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 11 3(1): 1-6.
6. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324(7329): 71-86.
7. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348(9038): 1329-39.
8. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103(2): 201-6.
9. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36(5): 1514-9.
10. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002; 106(3): 379-85.
11. Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 2001; 297(2): 496-500.
12. Maguire PB, Foy M, Fitzgerald DJ. Using proteomics to identify potential therapeutic targets in platelets. Biochem Soc Trans 2005; 33(Pt 2): 409-12.
13. Santoni V, Molloy M, Rabilloud T. Membrane proteins and proteomics: Un amour impossible? Electrophoresis 2000; 21(6): 1054-70.
14. Garcia A, Prabhakar S, Brock CJ, Pearce AC, Dwek RA, Watson SP, et al. Extensive analysis of the human platelet proteome by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2004; 4(3): 656-68.
15. O'Neill EE, Brock CJ, von Kriegsheim AF, Pearce AC, Dwek RA, Watson SP, et al. Towards complete analysis of the platelet proteome. Proteomics 2002; 2(3): 288-305.
16. Garcia A, Prabhakar S, Hughan S, Anderson TW, Brock CJ, Pearce AC, et al. Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood 2004; 103(6): 2088-95.
17. Martens L, Van Damme P, Van Damme J, Staes A, Timmerman E, Ghesquiere B, et al. The human platelet proteome mapped by peptide-centric proteomics: A functional protein profile. Proteomics 2005; 5 (12): 3193-204.
18. Moebius J, Zahedi RP, Lewandrowski U, Berger C, Walter U, Sickmann A. The human platelet membrane proteome reveals several new potential membrane proteins. Mol Cell Proteomics 2005; 4(11): 1754-61.
19. Garcia BA, Smalley DM, Cho H, Shabanowitz J, Ley K, Hunt DF. The platelet microparticle proteome. J Proteome Res 2005; 4(5): 1516-21
20. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197(11): 1585-98.
21. Pfister SL. Role of platelet microparticles in the production of thromboxane by rabbit pulmonary artery. Hypertension 2004; 43(2): 428-33.
22. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005; 67(1): 30-8.
23. Nanda N, Bao M, Lin H, Clauser K, Komuves L, Quertermous T, et al. Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J Biol Chem 2005; 280(26): 24680-9.
24. Munro S. Lipid rafts: Elusive or illusive? Cell 2003; 115(4): 377- 88.
25. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1(1): 31-9.
26. Del Pozo MA. Integrin signaling and lipid rafts. Cell Cycle 2004; 3(6): 725-8.
27. Sharma P, Varma R, Sarasij RC, Ira, Gousset K, Krishnamoorthy G, et al. Nanoscale organization of multiple GPI-anchored proteins in living cell membranes. Cell 2004; 116(4): 577-89.
28. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387(6633): 569-72.
29. Nichols BJ, Kenworthy AK, Polishchuk RS, Lodge R, Roberts TH, Hirschberg K, et al. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J Cell Biol 2001; 153(3): 529-41.
30. Ikonen E. Roles of lipid rafts in membrane transport. Curr Opin Cell Biol 2001; 13(4): 470-7.
31. Xavier R, Brennan T, Li Q, McCormack C, Seed B. Membrane compartmentation is required for efficient T cell activation. Immunity 1998; 8(6): 723-12.
32. Cheng PC, Dykstra ML, Mitchell RN, Pierce SK. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med 999; 190(11): 1549-60.
33. Field KA, Holowka D, Baird B. Compartmentalized activation of the high affinity immunoglobulin B receptor within membrane domains. J Biol Chem 1997; 272(7): 4276-80.
34. Lang ML, Shen L, Wade WF. Gamma-chain dependent recruitment of tyrosine kinases to membrane rafts by the human IgA receptor Fc alpha R. J Immunol 1999; 163(10): 5391-8.
35. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 1992; 68(3): 533-44.
36. Schuck S, Honsho M, Ekroos K, Shevchenko A, Simons K. Resistance of cell membranes to different detergents. Proc Natl Acad Sci U S A 2003; 100(10): 5795-800.
37. Waugh MG, Lawson D, Hsuan JJ. Epidermal growth factor receptor activation is localized within low-buoyant density, non-caveolar membrane domains. Biochem J 1999; 337 (Pt 3): 591-7.
38. Foster LJ, De Hoog CL, Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc Natl Acad Sci U S A 2003; 100(10): 5813-8.
39. Kabouridis PS, Janzen J, Magee AL, Ley SC. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol 2000; 30(3): 954-63.
40. Pizzo P, Giurisato E, Tassi M, Benedetti A, Pozzan T, Viola A. Lipid rafts and T cell receptor signaling: A critical re-evaluation. Eur J Immunol 2002; 32(11): 3082-91.
41. Horejsi V. Membrane rafts in immunoreceptor signaling: New doubts, new proofs? Trends Immunol 2002; 23(12): 562-4.
42. Drevot P, Langlet C, Guo XJ, Bernard AM, Colard O, Chauvin JP, et al. TCR signal initiation machinery is pre-assembled and activated in a subset of membrane rafts. EMBO J 2002; 21(8): 1899-908.
43. Zeyda M, Staffler G, Horejsi V, Waldhausl W, Stulnig TM. LAT displacement from lipid rafts as a molecular mechanism for the inhibition of T cell signaling by polyunsaturated fatty acids. J Biol Chem 2002; 277(32): 28418-23.
44. Dorahy DJ, Lincz LF, Meldrum CJ, Burns GF. Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Biochem J 1996; 319 (Pt 1): 67-72.
45. Gousset K, Wolkers WF, Tsvetkova NM, Oliver AE, Field CL, Walker NJ, et al. Evidence for a physiological role for membrane rafts in human platelets. J Cell Physiol 2002; 190(1): 117-28.
46. Heijnen HF, Van Lier M, Waaijenborg S, Ohno-Iwashita Y, Waheed AA, Inomata M, et al. Concentration of rafts in platelet filopodia correlates with recruitment of c-Src and CD63 to these domains. J Thromb Haemost 2003; 1(6): 1161-73.
47. Locke D, Chen H, Liu Y, Liu C, Kahn ML. Lipid rafts orchestrate signaling by the platelet receptor glycoprotein VI. J Biol Chem 2002; 277(21): 18801-9.
48. Shrimpton CN, Borthakur G, Larrucea S, Cruz MA, Dong JF, Lopez JA. Localization of the adhesion receptor glycoprotein Ib-IX-V complex to lipid rafts is required for platelet adhesion and activation. J Exp Med 2002; 196(8): 1057-66.
49. Ezumi Y, Kodama K, Uchiyama T, Takayama H. Constitutive and functional association of the platelet collagen receptor glycoprotein VI-Fc receptor gamma-chain complex with membrane rafts. Blood 2002; 99(9): 3250-5.
50. Young RM, Holowka D, Baird B. A lipid raft environment enhances Lyn kinase activity by protecting the active site tyrosine from dephosphorylation. J Biol Chem 2003; 278(23): 20746-52.
51. Pasquet JM, Gross B, Quek L, Asazuma N, Zhang W, Sommers CL, et al. LAT is required for tyrosine phosphorylation of phospholipase cgamma2 and platelet activation by the collagen receptor GPVI. Mol Cell Biol 1999; 19(12): 8326-34.
52. Gross BS, Lee JR, Clements JL, Turner M, Tybulewicz VL, Findell PR, et al. Tyrosine phosphorylation of SLP-76 is downstream of Syk following stimulation of the collagen receptor in platelets. J Biol Chem 1999; 274(9): 5963-71.
53. Baglia FA, Shrimpton CN, Lopez JA, Walsh PN. The glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane. J Biol Chem 2003; 278(24): 21744-50.
54. Bodin S, Giuriato S, Ragab J, Humbel BM, Viala C, Vieu C, et al. Production of phosphatidylinositol 3,4,5-trisphosphate and phosphatidic acid in platelet rafts: Evidence for a critical role of cholesterol-enriched domains in human platelet activation. Biochemistry 2001; 40(50): 15290-9.
55. Canobbio I, Stefanini L, Guidetti GF, Balduini C, Torti M. A new role for FcgammaRIIA in the potentiation of human platelet activation induced by weak stimulation. Cell Signal 2006; 18: 861-70.
56. Quinton TM, Kim S, Jin J, Kunapuli SP. Lipid rafts are required in Galpha(i) signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation. J Thromb Haemost 2005; 3(5): 1036-41.
57. Pralle A, Keller P, Florin EL, Simons K, Horber JK. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J Cell Biol 2000; 148(5): 997-1008.
58. von Haller PD, Donohoe S, Goodlett DR, Aebersold R, Watts JD. Mass spectrometric characterization of proteins extracted from Jurkat T cell detergent-resistant membrane domains. Proteomics 2001; 1(8): 1010-21
59. Li N, Mak A, Richards DP, Naber C, Keller BO, Li L, et al. Monocyte lipid rafts contain proteins implicated in vesicular trafficking and phagosome formation. Proteomics 2003; 3(4): 536-48.
60. Nebl T, Pestonjamasp KN, Leszyk JD, Crowley JL, On SW, Luna EJ. Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma membranes. J Biol Chem 2002; 277(45): 43399-409.
61. Bini L, Pacini S, Liberatori S, Valensin S, Pellegrini M, Raggiaschi R, et al. Extensive temporally regulated reorganization of the lipid raft proteome following T-cell antigen receptor triggering. Biochem J 2003; 369(Pt 2): 301-9.
62. Blonder J, Hale ML, Lucas DA, Schaefer CF, Yu LR, Conrads TP, et al. Proteomic analysis of detergent-resistant membrane rafts. Electrophoresis 2004; 25(9): 1307-18.
63. Garcia A, Zitzmann N, Watson SP. Analyzing the platelet proteome. Semin Thromb Hemost 2004; 30(4): 485-9.
64. Mairhofer M, Steiner M, Mosgoeller W, Prohaska R, Salzer U. Stomatin is a major lipid-raft component of platelet alpha granules. Blood 2002; 100(3): 897-904.
65. Wonerow P, Obergfell A, Wilde JI, Bobe R, Asazuma N, Brdicka T, et al. Differential role of glycolipid-enriched membrane domains in glycoprotein VI- and integrin-mediated phospholipase Cgamma2 regulation in platelets. Biochem J 2002; 364(Pt 3): 755-65.
66. Gousset K, Tsvetkova NM, Crowe JH, Tablin F. Important role of raft aggregation in the signaling events of cold-induced platelet activation. Biochim Biophys Acta 2004; 1660(1-2): 7-15.
67. Bae TJ, Kim MS, Kim JW, Kim BW, Choo HJ, Lee JW, et al. Lipid raft proteome reveals ATP synthase complex in the cell surface. Proteomics 2004; 4(11): 3536-48.
68. Marshall SJ, Asazuma N, Best D, Wonerow P, Salmon G, Andrews RK, et al. Glycoprotein IIb-IIIa-dependent aggregation by glycoprotein Ibalpha is reinforced by a Src family kinase inhibitor (PP1)-sensitive signalling pathway. Biochem J 2002; 361(Pt 2): 297-305.
69. Muszbek L, Laposata M. Glycoprotein Ib and glycoprotein IX in human platelets are acylated with palmitic acid through thioester linkages. J Biol Chem 1989; 264(17): 9716-9.
70. Bodin S, Soulet C, Tronchere H, Sie P, Gachet C, Plantavid M, et al. Integrin-dependent interaction of lipid rafts with the actin cytoskeleton in activated human platelets. J Cell Sci 2005; 118(Pt 4): 759-69.
71. Kwiatkowska K, Frey J, Sobota A. Phosphorylation of FcgammaRIIA is required for the receptor-induced actin rearrangement and capping: The role of membrane rafts. J Cell Sci 2003; 116(Pt 3): 537-50.
72. Meiri KF. Membrane/cytoskeleton communication. Subcell Biochem 2004; 37: 247-82.
73. Caroni P. New EMBO members' review: Actin cytoskeleton regulation through modulation of PI(4,5)P(2) rafts. EMBO J 2001; 20(16): 4332-6
74. Harder T, Simons K. Clusters of glycolipid and glycosylphosphatidylinositol-anchored proteins in lymphoid cells: accumulation of actin regulated by local tyrosine phosphorylation. Eur J Immunol 1999; 29(2): 556-62.
75. Chamberlain LH, Burgoyne RD, Gould GW. SNARE protein are highly enriched in lipid rafts in PC12 cells; implications for the spatial control of exooytosis. Proc Natl Acad Sci U S A 2001; 98(10): 5619-24.
76. Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C, et al. SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J 2001; 20(9): 2202-13
77. Wolkers WF, Looper SA, Fontanilla RA, Tsvetkova NM, Tablin F, Crowe JH. Temperature dependence of fluid phase endocytosis coincides with membrane properties of pig platelets. Biochim Biophys Acta 2003; 1612(2): 154-63.
78. Miura Y, Hanada K, Jones TL. G(s) signaling is intact after disruption of lipid rafts. Biochemistry 2001; 40(50): 15418-23.
79. Zhang B, Schmoyer D, Kirov S, Snoddy J. GOTree Machine (GOTM): A web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics 2004; 5(1): 16.
80. Sonnhammer EL, von Heijne G, Krogh A. A hidden Markov model for predicting transmembrane helices in protein sequences. Proc Int Conf Intell Syst Mol Biol 1998; 6: 175-82.
81. Simons K, Ehehalt R. Cholesterol, lipid rafts, and disease. J Clin Invest 2002; 110(5): 597-603.
82. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: In search of the 'magic bullet'. Nat Rev Drug Discov 2003; 2(10): 775-89.
83. Durr E, Yu J, Krasinska KM, Carver LA, Yates JR, Testa JE, et al. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol 2004; 22(8): 985-92.
84. Shi Y, Xiang R, Horvath C, Wilkins JA. Quantitative analysis of membrane proteins from breast cancer cell lines BT474 and MCF7 using multistep solid phase mass tagging and 2D LC/MS. J Proteome Res 2005; 4(4): 1427-33.
85. Butler GS, Overall CM. Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labeling and tandem mass spectrometry. Curr Pharm Des 2007; 13(3): 263-70.
86. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006; 12(10): 1255-9.
87. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 2005; 11(18): 2331-65.